Literature DB >> 23674524

Explicit consideration of baseline factors to assess recombinant tissue-type plasminogen activator response with respect to race and sex.

Pitchaiah Mandava1, Santosh B Murthy, Melody Munoz, Dawn McGuire, Roger P Simon, Andrei V Alexandrov, Karen C Albright, Amelia K Boehme, Sheryl Martin-Schild, Sharyl Martini, Thomas A Kent.   

Abstract

BACKGROUND AND
PURPOSE: Sex and race reportedly influence outcome after recombinant tissue-type plasminogen activator (rtPA). It is, however, unclear whether baseline imbalances (eg, stroke severity) or lack of response to thrombolysis is responsible. We applied balancing methods to test the hypothesis that race and sex influence outcome after rtPA independent of baseline conditions.
METHODS: We mapped group outcomes from the National Institute of Neurological Disorders and Stroke (NINDS) dataset based on race and sex onto a surrogate-control function to assess differences from expected outcomes at their respective National Institutes of Health Stroke Scale and age. Outcomes were also compared for subjects matched individually on key baseline factors using NINDS and 2 recent datasets from southeastern United States.
RESULTS: At similar National Institutes of Health Stroke Scale and age, 90-day good outcomes (modified Rankin Score, 0-2) in NINDS were similarly improved after rtPA for white men and women. There was a strong trend for improvement in black men. Conversely, black women treated with rtPA showed response rates no different from the controls. After baseline matching, there were nonsignificant trends in outcomes except for significantly fewer good outcomes in black versus matched white women (37% versus 63%; P=0.027). Pooling the 3 datasets showed a similar trend for poorer short-term outcome for black women (P=0.054; modified Rankin Score, 0-1).
CONCLUSIONS: Matching for key baseline factors indicated that race and sex influence outcome most strikingly in black women who demonstrated poorest outcomes after rtPA. This finding supports the hypothesis that poor response to rtPA, rather than differences in baseline conditions, contributes to the worse outcome. This finding requires prospective confirmation.

Entities:  

Keywords:  alteplase; race; recombinant tissue-type plasminogen activator; sex; stroke; thrombolysis

Mesh:

Substances:

Year:  2013        PMID: 23674524      PMCID: PMC5535075          DOI: 10.1161/STROKEAHA.113.001116

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  28 in total

1.  Committee for Proprietary Medicinal Products (CPMP): points to consider on adjustment for baseline covariates.

Authors: 
Journal:  Stat Med       Date:  2004-03-15       Impact factor: 2.373

2.  Racial-ethnic disparities in stroke care: the American experience: a statement for healthcare professionals from the American Heart Association/American Stroke Association.

Authors:  Salvador Cruz-Flores; Alejandro Rabinstein; Jose Biller; Mitchell S V Elkind; Patrick Griffith; Philip B Gorelick; George Howard; Enrique C Leira; Lewis B Morgenstern; Bruce Ovbiagele; Eric Peterson; Wayne Rosamond; Brian Trimble; Amy L Valderrama
Journal:  Stroke       Date:  2011-05-26       Impact factor: 7.914

3.  Trends in thrombolytic use for ischemic stroke in the United States.

Authors:  Margaret C Fang; David M Cutler; Allison B Rosen
Journal:  J Hosp Med       Date:  2010-09       Impact factor: 2.960

4.  Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort.

Authors:  W D Rosamond; A R Folsom; L E Chambless; C H Wang; P G McGovern; G Howard; L S Copper; E Shahar
Journal:  Stroke       Date:  1999-04       Impact factor: 7.914

5.  Ethnic disparities in stroke: the scope of the problem.

Authors:  G Howard; V J Howard
Journal:  Ethn Dis       Date:  2001       Impact factor: 1.847

6.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

7.  Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial.

Authors: 
Journal:  Stroke       Date:  1997-11       Impact factor: 7.914

8.  Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial.

Authors:  Timothy John Ingall; William Michael O'Fallon; Kjell Asplund; Lewis Robert Goldfrank; Vicki S Hertzberg; Thomas Arthur Louis; Teresa J Hengy Christianson
Journal:  Stroke       Date:  2004-09-02       Impact factor: 7.914

9.  The relationship between cardiometabolic and hemostatic variables: influence of race.

Authors:  Arlette Perry; Xuewen Wang; Ronald Goldberg; Robert Ross; Loreto Jackson
Journal:  Metabolism       Date:  2008-02       Impact factor: 8.694

10.  A user's guide to the NINDS rt-PA stroke trial database.

Authors:  Robert J Dachs; John H Burton; Jeremy Joslin
Journal:  PLoS Med       Date:  2008-05-20       Impact factor: 11.069

View more
  6 in total

Review 1.  Sex differences in stroke therapies.

Authors:  Farida Sohrabji; Min Jung Park; Amanda H Mahnke
Journal:  J Neurosci Res       Date:  2017-01-02       Impact factor: 4.164

Review 2.  Racial and ethnic disparities in stroke outcomes: a scoping review of post-stroke disability assessment tools.

Authors:  Suzanne Perea Burns; Brandi M White; Gayenell Magwood; Charles Ellis; Ayaba Logan; Joy N Jones Buie; Robert J Adams
Journal:  Disabil Rehabil       Date:  2018-03-23       Impact factor: 3.033

Review 3.  The Importance of Considering Sex Differences in Translational Stroke Research.

Authors:  Hilda Ahnstedt; Louise D McCullough; Marilyn J Cipolla
Journal:  Transl Stroke Res       Date:  2016-02-01       Impact factor: 6.829

4.  Blood transcriptome changes after stroke in an African American population.

Authors:  Robert Meller; Andrea N Pearson; Jimmaline J Hardy; Casey L Hall; Dawn McGuire; Michael R Frankel; Roger P Simon
Journal:  Ann Clin Transl Neurol       Date:  2016-01-15       Impact factor: 4.511

5.  Efficacy of Novel Carbon Nanoparticle Antioxidant Therapy in a Severe Model of Reversible Middle Cerebral Artery Stroke in Acutely Hyperglycemic Rats.

Authors:  Roderic H Fabian; Paul J Derry; Harriett Charmaine Rea; William V Dalmeida; Lizanne G Nilewski; William K A Sikkema; Pitchaiah Mandava; Ah-Lim Tsai; Kimberly Mendoza; Vladimir Berka; James M Tour; Thomas A Kent
Journal:  Front Neurol       Date:  2018-04-09       Impact factor: 4.003

Review 6.  Thrombolysis for acute ischaemic stroke.

Authors:  Joanna M Wardlaw; Veronica Murray; Eivind Berge; Gregory J del Zoppo
Journal:  Cochrane Database Syst Rev       Date:  2014-07-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.